ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Merck KGaA, Darmstadt, Germany and GlaxoSmithKline side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Merck KGaA, Darmstadt, GermanyGlaxoSmithKline
studies on the registry5234,198
open to participants now17135
phase 3 studies under way776
reach primary completion within a year766
programswith a study of their own in two years1488+17 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseMerck KGaA, Darmstadt, GermanyGlaxoSmithKline
Phase 1

Merck KGaA, Darmstadt, Germany: 6 of its 14 programs at phase 1

  1. PARP1 Inhibitor HRS-1167phase 1
  2. M5542phase 1
  3. Anti-MUC-1/Anti-CD40 Bispecific Antibody M0324phase 1
  4. M7437phase 1
  5. Contraceptives, Oral, Combinedphase 1

and 1 more — sign in to see them all

43%

GlaxoSmithKline: 19 of its 88 programs at phase 1

  1. Pn-MAPS30plusphase 1
  2. GSK4771261phase 1
  3. Antibody-drug Conjugate GSK5533524phase 1
  4. ganfeborolephase 1
  5. GSK4425689Aphase 1

and 14 more — sign in to see them all

22%
Phase 2

Merck KGaA, Darmstadt, Germany: 2 of its 14 programs at phase 2

  1. mirdametinibphase 2
  2. pimicotinibphase 2
14%

GlaxoSmithKline: 36 of its 88 programs at phase 2

  1. dezecapavirphase 2
  2. nelistotugphase 2
  3. GSK3862995Bphase 2
  4. VH4524184phase 2
  5. nirogacestatphase 2

and 31 more — sign in to see them all

41%
Phase 3

Merck KGaA, Darmstadt, Germany: 3 of its 14 programs at phase 3

  1. enpatoranphase 3
  2. precemtabart tocentecanphase 3
  3. evobrutinibphase 3
21%

GlaxoSmithKline: 23 of its 88 programs at phase 3

  1. belantamab mafodotinphase 3
  2. felcorekibartphase 3
  3. risvutatug rezetecanphase 3
  4. velzatinibphase 3
  5. efimosfermin alfaphase 3

and 18 more — sign in to see them all

26%
Approved, new studies

Merck KGaA, Darmstadt, Germany: 3 of its 14 programs at approved, new studies

  1. nirogacestatapproved, new study
  2. follitropin alfaapproved, new study
  3. lutropin alfaapproved, new study
21%

GlaxoSmithKline: 10 of its 88 programs at approved, new studies

  1. dostarlimabapproved, new study
  2. cabotegravirapproved, new study
  3. depemokimabapproved, new study
  4. belimumabapproved, new study
  5. niraparibapproved, new study

and 5 more — sign in to see them all

11%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Merck KGaA, Darmstadt, Germany5 readouts · 2 phase 3

Merck KGaA, Darmstadt, Germany, Nov ’26: 1 program whose next study reaches primary completion

  1. mirdametinibphase 2 · Nov 27 · NCT06997276
··

Merck KGaA, Darmstadt, Germany, Feb ’27: 1 program whose next study reaches primary completion

  1. PARP1 Inhibitor HRS-1167phase 1 · Feb 22 · NCT06421935
··

Merck KGaA, Darmstadt, Germany, May ’27: 1 program whose next study reaches primary completion

  1. nirogacestatapproved, new study · May 28 · NCT07170644
···

Merck KGaA, Darmstadt, Germany, Sep ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. follitropin alfaapproved, new study · Sep 30 · NCT07340827
  2. lutropin alfaapproved, new study · Sep 30 · NCT07340827
·
GlaxoSmithKline40 readouts · 8 phase 3

GlaxoSmithKline, Nov ’26: 4 programs whose next study reaches primary completion, 2 in phase 3

  1. Pn-MAPS30plusphase 1 · Nov 19 · NCT07428759
  2. dostarlimabapproved, new study · Nov 23 · NCT06567782
  3. Pentetic Acidphase 3 · Nov 23 · NCT07596199
  4. niraparibapproved, new study · Nov 26 · NCT03981796

GlaxoSmithKline, Dec ’26: 6 programs whose next study reaches primary completion, 2 in phase 3

  1. Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccinephase 1 · Dec 3 · NCT07464314
  2. momelotinibphase 3 · Dec 11 · NCT03441113
  3. GSK3862995Bphase 2 · Dec 16 · NCT06154837
  4. HFA-152aphase 3 · Dec 28 · NCT07645248
  5. norfluranephase 3 · Dec 28 · NCT07645248

and 1 more — sign in to see them all

GlaxoSmithKline, Jan ’27: 4 programs whose next study reaches primary completion

  1. Adjuvanted RSVPreF3 vaccinephase 2 · Jan 12 · NCT07092865
  2. velzatinibphase 3 · Jan 12 · NCT07862114
  3. SOC INSTI-based ARTphase 1 · Jan 22 · NCT07053384
  4. VH3810109phase 2 · Jan 22 · NCT07053384

GlaxoSmithKline, Feb ’27: 1 program whose next study reaches primary completion

  1. dezecapavirphase 2 · Feb 18 · NCT07934719

GlaxoSmithKline, Mar ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. depemokimabapproved, new study · Mar 1 · NCT07671001
  2. CAB ULAphase 3 · Mar 8 · NCT06786520
  3. cabotegravirapproved, new study · Mar 8 · NCT06786520
  4. camlipixantphase 3 · Mar 9 · NCT07519395
  5. ozureprubartphase 2 · Mar 16 · NCT07220811

and 1 more — sign in to see them all

GlaxoSmithKline, Apr ’27: 2 programs whose next study reaches primary completion

  1. felcorekibartphase 3 · Apr 13 · NCT07712393
  2. as01ephase 2 · Apr 23 · NCT07036159

GlaxoSmithKline, May ’27: 5 programs whose next study reaches primary completion

  1. Candidate UTI vaccine HTD formulation 2phase 2 · May 3 · NCT06702449
  2. Candidate UTI vaccine low dose formulation 1phase 2 · May 3 · NCT06702449
  3. VH4770359phase 1 · May 5 · NCT07525544
  4. gepotidacinphase 3 · May 17 · NCT07645235
  5. GSK4771261phase 1 · May 20 · NCT07600450

GlaxoSmithKline, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. Bevacizumabphase 2 · Jun 21 · NCT06796907
  2. belimumabapproved, new study · Jun 29 · NCT06411249
  3. Low dose Strep A Alumphase 1 · Jun 29 · NCT07085702
  4. Low dose Strep A AS37phase 1 · Jun 29 · NCT07085702

GlaxoSmithKline, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mRNA Seasonal Flu vaccinephase 3 · Jul 9 · NCT07851246

GlaxoSmithKline, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. belantamabphase 2 · Aug 5 · NCT07742527
  2. shingrixapproved, new study · Aug 23 · NCT05371080

GlaxoSmithKline, Sep ’27: 1 program whose next study reaches primary completion

  1. mocertatug rezetecanphase 3 · Sep 22 · NCT06431594

GlaxoSmithKline, Oct ’27: 4 programs whose next study reaches primary completion

  1. GSK3772701phase 2 · Oct 8 · NCT07545681
  2. efimosfermin alfaphase 3 · Oct 13 · NCT07358546
  3. Anti-PSMA/Anti-CD3 T-cell Engager GSK5458514phase 2 · Oct 26 · NCT06990880
  4. VH4524184phase 2 · Oct 28 · NCT07202546
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Merck KGaA, Darmstadt, Germany

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

GlaxoSmithKline

New programs 4

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 10

Where they overlap

Conditions where at least two of them have programs: 12 in all. A program counts in each condition its studies name most.

ConditionMerck KGaA, Darmstadt, GermanyGlaxoSmithKline
Carcinoma, Non-Small-Cell Lungboth · compare here

Merck KGaA, Darmstadt, Germany in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. mirdametinibphase 2
  2. Anti-MUC-1/Anti-CD40 Bispecific Antibody M0324phase 1

Their studies: Merck KGaA, Darmstadt, Germany’s studies of Carcinoma, Non-Small-Cell Lung in search

GlaxoSmithKline in Carcinoma, Non-Small-Cell Lung: 8 programs

  1. risvutatug rezetecanphase 3
  2. momelotinibphase 3
  3. neladalkibphase 3
  4. feladilimabphase 3
  5. nelistotugphase 2

and 3 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of Carcinoma, Non-Small-Cell Lung in search

Neoplasmsboth · compare here

Merck KGaA, Darmstadt, Germany in Neoplasms: 1 program

  1. pimicotinibphase 2

Their studies: Merck KGaA, Darmstadt, Germany’s studies of Neoplasms in search

Ovarian Neoplasmsboth · compare here

Merck KGaA, Darmstadt, Germany in Ovarian Neoplasms: 2 programs

  1. PARP1 Inhibitor HRS-1167phase 1
  2. nirogacestatapproved, new study

Their studies: Merck KGaA, Darmstadt, Germany’s studies of Ovarian Neoplasms in search

GlaxoSmithKline in Ovarian Neoplasms: 6 programs

  1. mocertatug rezetecanphase 3
  2. nirogacestatphase 2
  3. Bevacizumabphase 2
  4. ivonescimabphase 2
  5. dostarlimabapproved, new study

and 1 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of Ovarian Neoplasms in search

Colorectal Neoplasmsboth · compare here

Merck KGaA, Darmstadt, Germany in Colorectal Neoplasms: 1 program

  1. precemtabart tocentecanphase 3

Their studies: Merck KGaA, Darmstadt, Germany’s studies of Colorectal Neoplasms in search

Lupus Erythematosus, Systemicboth · compare here

Merck KGaA, Darmstadt, Germany in Lupus Erythematosus, Systemic: 2 programs

  1. enpatoranphase 3
  2. evobrutinibphase 3

Their studies: Merck KGaA, Darmstadt, Germany’s studies of Lupus Erythematosus, Systemic in search

GlaxoSmithKline in Lupus Erythematosus, Systemic: 4 programs

  1. GSK5926371phase 2
  2. GSK4527363phase 1
  3. GSK4347859phase 1
  4. belimumabapproved, new study

Their studies: GlaxoSmithKline’s studies of Lupus Erythematosus, Systemic in search

Multiple Myelomaboth · compare here

Merck KGaA, Darmstadt, Germany in Multiple Myeloma: 1 program

  1. nirogacestatapproved, new study

Their studies: Merck KGaA, Darmstadt, Germany’s studies of Multiple Myeloma in search

GlaxoSmithKline in Multiple Myeloma: 5 programs

  1. belantamab mafodotinphase 3
  2. feladilimabphase 3
  3. nirogacestatphase 2
  4. belantamabphase 2
  5. isatuximabphase 2

Their studies: GlaxoSmithKline’s studies of Multiple Myeloma in search

Breast Neoplasmsboth · compare here

Merck KGaA, Darmstadt, Germany in Breast Neoplasms: 2 programs

  1. M7437phase 1
  2. nirogacestatapproved, new study

Their studies: Merck KGaA, Darmstadt, Germany’s studies of Breast Neoplasms in search

GlaxoSmithKline in Breast Neoplasms: 3 programs

  1. nirogacestatphase 2
  2. Bevacizumabphase 2
  3. niraparibapproved, new study

Their studies: GlaxoSmithKline’s studies of Breast Neoplasms in search

Prostatic Neoplasmsboth · compare here

Merck KGaA, Darmstadt, Germany in Prostatic Neoplasms: 1 program

  1. PARP1 Inhibitor HRS-1167phase 1

Their studies: Merck KGaA, Darmstadt, Germany’s studies of Prostatic Neoplasms in search

Arthritis, Rheumatoidboth · compare here

Merck KGaA, Darmstadt, Germany in Arthritis, Rheumatoid: 1 program

  1. evobrutinibphase 3

Their studies: Merck KGaA, Darmstadt, Germany’s studies of Arthritis, Rheumatoid in search

GlaxoSmithKline in Arthritis, Rheumatoid: 1 program

  1. belimumabapproved, new study

Their studies: GlaxoSmithKline’s studies of Arthritis, Rheumatoid in search

Autoimmune Diseasesboth · compare here

Merck KGaA, Darmstadt, Germany in Autoimmune Diseases: 1 program

  1. evobrutinibphase 3

Their studies: Merck KGaA, Darmstadt, Germany’s studies of Autoimmune Diseases in search

GlaxoSmithKline in Autoimmune Diseases: 1 program

  1. belantamabphase 2

Their studies: GlaxoSmithKline’s studies of Autoimmune Diseases in search

Desmoid Tumorsboth · compare here

Merck KGaA, Darmstadt, Germany in Desmoid Tumors: 1 program

  1. nirogacestatapproved, new study

Their studies: Merck KGaA, Darmstadt, Germany’s studies of Desmoid Tumors in search

GlaxoSmithKline in Desmoid Tumors: 1 program

  1. nirogacestatphase 2

Their studies: GlaxoSmithKline’s studies of Desmoid Tumors in search

Leukemiaboth · compare here

Merck KGaA, Darmstadt, Germany in Leukemia: 1 program

  1. nirogacestatapproved, new study

Their studies: Merck KGaA, Darmstadt, Germany’s studies of Leukemia in search

GlaxoSmithKline in Leukemia: 1 program

  1. nirogacestatphase 2

Their studies: GlaxoSmithKline’s studies of Leukemia in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Merck KGaA, Darmstadt, Germany 9 of 14 · GlaxoSmithKline 65 of 88 programs (25 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (GlaxoSmithKline: 17).